Beth israel medical center
Brigham and womens hospital
Dana farber cancer institute
Hackensack university medical center
Jacobi medical center
Lenox hill hospital
Montefiore medical center
New york and presbyterian hospital
New york methodist hospital
North shore university hospital
Bellevue Hospital Center
Memorial Hospital For Cancer and Allied Diseases
Clinical impact of residual extraretroperitoneal masses in patients with advanced nonseminomatous germ cell testicular cancer.
Urology., Jan;79(1):156-9 (2012)
Phase I study of flavopiridol with oxaliplatin and fluorouracil/leucovorin in advanced solid tumors.
Clin. Cancer Res., Dec;15(23):7405-11 (2009)
TI-CE high-dose chemotherapy for patients with previously treated germ cell tumors: results and prognostic factor analysis.
J. Clin. Oncol., Apr;28(10):1706-13 (2010)
CT findings of chemotherapy-induced toxicity: what radiologists need to know about the clinical and radiologic manifestations of chemotherapy toxicity.
Radiology., Jan;258(1):41-56 (2011)
The total number of retroperitoneal lymph nodes resected impacts clinical outcome after chemotherapy for metastatic testicular cancer.
Urology., Jun;75(6):1431-5 (2010)
Contemporary lymph node counts during primary retroperitoneal lymph node dissection.
Urology., Feb;77(2):368-72 (2011)
Outcomes after resection of postchemotherapy residual neck mass in patients with germ cell tumors--an update.
Urology., Mar;77(3):655-9 (2011)
Treatment of epidural spinal cord involvement from germ cell tumors with chemotherapy.
Cancer., May;117(9):1911-6 (2011)
Body mass index is associated with higher lymph node counts during retroperitoneal lymph node dissection.
Urology., Feb;79(2):361-4 (2012)
Progression-free and overall survival in patients with relapsed/refractory germ cell tumors treated with single-agent chemotherapy: endpoints for clinical trial design.
Cancer., Feb;118(4):981-6 (2012)
Outcomes in patients with clinical stage III NSGCT who achieve complete clinical response to chemotherapy at extraretroperitoneal disease site.
Urology., May;79(5):1079-84 (2012)
Paclitaxel plus Ifosfamide followed by high-dose carboplatin plus etoposide in previously treated germ cell tumors.
J. Clin. Oncol., Jan;25(1):85-90 (2007)
Pathologic findings and clinical outcome of patients undergoing retroperitoneal lymph node dissection after multiple chemotherapy regimens for metastatic testicular germ cell tumors.
Cancer., Feb;109(3):528-35 (2007)
Improved clinical outcome in recent years for men with metastatic nonseminomatous germ cell tumors.
J. Clin. Oncol., Dec;25(35):5603-8 (2007)
Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors.
J. Clin. Oncol., Jan;25(3):247-56 (2007)
Incidence of disease outside modified retroperitoneal lymph node dissection templates in clinical stage I or IIA nonseminomatous germ cell testicular cancer.
J. Urol., Mar;177(3):937-42; discussion 942-3 (2007)
Clinical outcome following post-chemotherapy retroperitoneal lymph node dissection in men with intermediate- and poor-risk nonseminomatous germ cell tumour.
BJU Int., May;99(5):993-7 (2007)
Phase II trial of ixabepilone in patients with cisplatin-refractory germ cell tumors.
Invest New Drugs., Oct;25(5):487-90 (2007)
Curing germ cell tumors after failure of high-dose chemotherapy: progress through clinical trials.
Nat Clin Pract Oncol., Sep;4(9):508-9 (2007)
Nonrandomized comparison of primary chemotherapy and retroperitoneal lymph node dissection for clinical stage IIA and IIB nonseminomatous germ cell testicular cancer.
J. Clin. Oncol., Dec;25(35):5597-602 (2007)